Tafamidis patent expiration date?

See the DrugPatentWatch profile for Tafamidis

When Does The Patent Exclusivity Expire For Tafamidis?

Tafamidis, marketed under the brand name Vyndaqel, is a medication used to treat transthyretin amyloidosis (ATTR amyloidosis), a genetic condition that affects the production of a protein vital for the liver and nerves. The patent for this drug is held by Pfizer, one of the most influential pharmaceutical companies globally.

According to the patent database available at DrugPatentWatch.com [1], the United States patent (US 9149324) for Tafamidis is set to expire on August 28, 2029. This patent was issued in 2015.

What Are The Implications Of Patent Expiration For Tafamidis?

When the patent expires, other companies can begin to develop and market generic or biosimilar versions of the drug. This could lead to increased competition, potentially reducing prices and improving patient access to the treatment.

Is Tafamidis Under Litigation?

While there might not be specific information on ongoing litigations surrounding the Tafamidis patent, challenges to patents like this are common and often lead to legal disputes between the patent holder and generic manufacturers wishing to bring their products to market.

What Next For Tafamidis?

The expiration of the patent for Tafamidis marks an important milestone but it also presents new questions about the role of generic or biosimilar versions in the market. The impact on prices and patients' access to treatment will depend on several factors, including regulatory approval and competition from generic manufacturers.

References:
[1] DrugPatentWatch.com: US patent US9149324 for Tafamidis - https://drugs-patent.us/ep/9149324